Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T80526 Target Info
Target Name Casein kinase II alpha prime (CSNK2A2)
Synonyms Casein kinase II subunit alpha'; CK2A2; CK II alpha'
Target Type Patented-recorded Target
Gene Name CSNK2A2
Biochemical Class Kinase
UniProt ID
CSK22_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US8940736
Title Imidazotriazinecarbonitriles useful as kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0XY1Z Drug Info IC50 = 0.07 nM Click to Show More [1]
2 D01QPX Drug Info IC50 = 0.09 nM [1]
3 D0D2CR Drug Info IC50 = 0.87 nM [1]
Patent ID US8940736
Title Imidazotriazinecarbonitriles useful as kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0XY1Z Drug Info IC50 = 0.07 nM Click to Show More [1]
2 D01QPX Drug Info IC50 = 0.09 nM [1]
3 D0D2CR Drug Info IC50 = 0.87 nM [1]
Patent ID US8940736
Title Imidazotriazinecarbonitriles useful as kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0XY1Z Drug Info IC50 = 0.07 nM Click to Show More [1]
2 D01QPX Drug Info IC50 = 0.09 nM [1]
3 D0D2CR Drug Info IC50 = 0.87 nM [1]
Patent ID US8791257
Title Substituted pyrrolotriazines as protein kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0NM6I Drug Info IC50 = 2.8 nM Click to Show More [2]
2 D0H6DS Drug Info IC50 = 50 nM [2]
3 D0E7ZS Drug Info IC50 = 70 nM [2]
Patent ID US8791257
Title Substituted pyrrolotriazines as protein kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0NM6I Drug Info IC50 = 2.8 nM Click to Show More [2]
2 D0H6DS Drug Info IC50 = 50 nM [2]
3 D0E7ZS Drug Info IC50 = 70 nM [2]
Patent ID US8791257
Title Substituted pyrrolotriazines as protein kinase inhibitors
Abstract The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) pyrrolotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
Applicant(s) Bristol-Myers Squibb Company
Representative Drug(s) D0NM6I Drug Info IC50 = 2.8 nM Click to Show More [2]
2 D0H6DS Drug Info IC50 = 50 nM [2]
3 D0E7ZS Drug Info IC50 = 70 nM [2]
References  Top
REF 1 Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736.
REF 2 Substituted pyrrolotriazines as protein kinase inhibitors. US8791257.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.